Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) CFO Scott A. Holmes sold 2,582 shares of Keryx Biopharmaceuticals stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $6.03, for a total transaction of $15,569.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Keryx Biopharmaceuticals, Inc. (KERX) traded up 4.18% during trading on Tuesday, hitting $6.48. 2,334,174 shares of the stock were exchanged. The stock’s 50 day moving average is $6.89 and its 200-day moving average is $6.79. Keryx Biopharmaceuticals, Inc. has a one year low of $4.11 and a one year high of $8.38. The company’s market cap is $769.50 million.

COPYRIGHT VIOLATION WARNING: “Scott A. Holmes Sells 2,582 Shares of Keryx Biopharmaceuticals, Inc. (KERX) Stock” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/31/scott-a-holmes-sells-2582-shares-of-keryx-biopharmaceuticals-inc-kerx-stock.html.

A number of research analysts recently issued reports on KERX shares. Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 16th. Maxim Group restated a “buy” rating and set a $9.00 price objective on shares of Keryx Biopharmaceuticals in a research report on Thursday, July 20th. Morgan Stanley restated an “equal weight” rating and set a $7.00 price objective (up previously from $4.00) on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. Cowen and Company restated a “market perform” rating on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. Finally, ValuEngine downgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, September 21st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company’s stock. Keryx Biopharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $7.48.

Several institutional investors and hedge funds have recently modified their holdings of KERX. Wells Fargo & Company MN increased its holdings in shares of Keryx Biopharmaceuticals by 21.3% during the first quarter. Wells Fargo & Company MN now owns 73,926 shares of the biopharmaceutical company’s stock valued at $455,000 after purchasing an additional 12,987 shares during the period. Parametric Portfolio Associates LLC increased its holdings in shares of Keryx Biopharmaceuticals by 60.1% during the first quarter. Parametric Portfolio Associates LLC now owns 192,982 shares of the biopharmaceutical company’s stock valued at $1,189,000 after purchasing an additional 72,436 shares during the period. Stifel Financial Corp increased its holdings in shares of Keryx Biopharmaceuticals by 11.5% during the first quarter. Stifel Financial Corp now owns 33,736 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 3,478 shares during the period. American International Group Inc. increased its holdings in shares of Keryx Biopharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 48,622 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 3,220 shares during the period. Finally, Legal & General Group Plc increased its holdings in shares of Keryx Biopharmaceuticals by 1.2% during the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 300 shares during the period. 65.20% of the stock is currently owned by institutional investors.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Insider Buying and Selling by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.